Stock Research

US equities were little changed on Monday after President Donald Trump announced an increase in global tariffs to 15%, following a Supreme Court ruling that struck down his earlier “reciprocal” tariff framework. The S&P 500 hovered around the flatline during the session, while the Dow Jones Industrial Average and the Nasdaq Composite also traded with… Continue reading US stocks open flat after Trump raises global tariffs to 15%

Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart: a new injector pen, a new box, another reminder to refill, and one more item for the sharps bin. Eli Lilly is trying to make that routine feel less like a chore. The company says it has launched a new Zepbound KwikPen… Continue reading Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push

Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines. The move comes as the drugmaker seeks to prepare for mounting sales pressure later this decade, driven by the looming loss of exclusivity for… Continue reading Merck creates separate oncology arm ahead of Keytruda patent loss

Finland’s IQM is positioning itself at the centre of Europe’s quantum technology ambitions as it prepares to enter public markets in the US. According to a CNBC report, the company said on Monday it plans to merge with Real Asset Acquisition Corp, a special purpose acquisition company, in a deal that would value IQM at… Continue reading Finland’s IQM leads Europe’s quantum push with US listing plan

Arcellx stock (NASDAQ: ACLX) climbed roughly 80% in premarket trade on Monday after Gilead Sciences agreed to buy the cancer-therapy developer in a $7.8 billion all-cash deal. The stock’s move wasn’t a mystery rally. The surge was a classic takeover repricing: once Gilead and Arcellx signed a definitive deal at $115 a share, traders quickly… Continue reading Why is Arcellx stock up 80% today? Gilead’s $7.8B answer

In a sweeping and provocative macro-analysis titled “The 2028 Global Intelligence Crisis,” Citrini Research has outlined a sobering vision of a financial future where the very success of Artificial Intelligence becomes the primary engine of economic instability. The report, co-authored by Alap Shah, suggests that by June 2028, the global economy may be caught in… Continue reading Citrini research: S&P 500 to drop 38% from 2026 highs by June 2028

US stock index futures declined on Monday as investors reacted to renewed tariff uncertainty after US President Donald Trump announced a new 15% global duty, even after a Supreme Court ruling struck down most of his earlier levies. The Supreme Court, in a 6–3 decision on Friday, voided a large portion of tariffs imposed last… Continue reading S&P and Dow Jones futures fall as Trump tariffs revive uncertainty

Shares of Novo Nordisk fell sharply after the company said its next-generation obesity drug CagriSema delivered weaker weight-loss results than a rival treatment from Eli Lilly and Company. Novo said on Monday that patients treated with a standard dose of CagriSema achieved average weight loss of 20.2% after 84 weeks, compared with 23.6% for Lilly’s… Continue reading Novo stock drops 15% as obesity drug falls short in key trial

Rolls-Royce share price continued soaring last week and reached a record high as market participants waited for its financial results. It jumped to 1,353p, up by 120% in the last 12 months, bringing its market capitalization to over $152 billion. This rally may continue this week as it releases its financial results. Rolls-Royce Holdings to… Continue reading Rolls-Royce share price targets 1,500p ahead of earnings and buyback